Scarica l'app Stockscreener
5.67
14.78%
0.73
Dopo l'orario di chiusura:
5.70
0.03
+0.53%
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Oppenheimer Raises AQST Target Price, Shares Surge - StocksToTrade
Aquestive Therapeutics (NASDAQ:AQST) Reaches New 12-Month HighStill a Buy? - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Aquestive Therapeutics (NASDAQ:AQST) - MarketBeat
After Leaping 28% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - 富途牛牛
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday - Benzinga
Aug Technicals: What is the earnings history of Aquestive Therapeutics IncJuly 2025 Macro Moves & Verified Trade Idea Suggestions - khodrobank.com
Aquestive Therapeutics’ SWOT analysis: needle-free epinephrine stock poised for growth - Investing.com Canada
Macro Review: What is Aquestive Therapeutics Inc. s P E ratio telling usQuarterly Profit Report & Daily Technical Forecast Reports - khodrobank.com
Aquestive Therapeutics rises after pricing $85M stock offering - MSN
Aquestive Therapeutics (NASDAQ:AQST) Trading Up 5.2%Here's Why - MarketBeat
Aquestive Therapeutics Inc. stock trend forecastWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Whats the fair value of Aquestive Therapeutics Inc stockJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - khodrobank.com
Profit Recap: Whats the RSI of Aquestive Therapeutics Inc stock2025 Market Sentiment & Target Return Focused Stock Picks - khodrobank.com
Value Recap: What are Aquestive Therapeutics Inc.’s recent SEC filings showing - khodrobank.com
Performance Recap: Is Adtalem Global Education Inc being accumulated by smart moneyRate Cut & AI Enhanced Trading Alerts - خودرو بانک
Analyst Downgrade: What is the earnings history of Aquestive Therapeutics Inc2025 Sector Review & Fast Entry High Yield Tips - خودرو بانک
Buyout Rumor: Is Aquestive Therapeutics Inc forming a bullish divergenceRecession Risk & Short-Term High Return Strategies - khodrobank.com
Aug Mood: Can Aquestive Therapeutics Inc. grow without external fundingJuly 2025 Action & AI Forecast for Swing Trade Picks - خودرو بانک
Aug Summary: Is Aquestive Therapeutics Inc. stock good for income investorsEntry Point & Consistent Profit Trading Strategies - khodrobank.com
Oppenheimer Issues Positive Forecast for Aquestive Therapeutics (NASDAQ:AQST) Stock Price - MarketBeat
Peter E. Boyd Sells 15,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Trading Down 6.4% Following Insider Selling - MarketBeat
Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts - TipRanks
Aquestive Therapeutics Highlights at Global Investor Conference - MSN
Aquestive Therapeutics, Inc. $AQST Shares Bought by Everstar Asset Management LLC - MarketBeat
Aquestive Bets Big On Oral Epinephrine’s Market Debut - Finimize
Analysts Offer Predictions for AQST Q3 Earnings - MarketBeat
Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $8 - 富途牛牛
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Upgraded by Lifesci Capital - MarketBeat
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - MSN
Aquestive Therapeutics SVP sells $79,500 in shares By Investing.com - Investing.com South Africa
Aquestive therapeutics (AQST) COO Jung Cassie sells $310,900 in shares By Investing.com - Investing.com Australia
Aquestive Therapeutics SVP sells $79,500 in shares - Investing.com
Aquestive therapeutics (AQST) COO Jung Cassie sells $310,900 in shares - Investing.com
Aquestive Therapeutics at H.C. Wainwright: Anaphylm™ Poised for Growth - Investing.com
Aquestive Therapeutics at H.C. Wainwright: Anaphylm™ Poised for Growth By Investing.com - Investing.com Canada
Multi Factor Analysis Ranks Aquestive Therapeutics Inc. as Strong BuyMarket Activity Report & Community Consensus Picks - beatles.ru
Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy Market - TipRanks
Aquestive Therapeutics says FDA AdCom not needed for review of Anaphylm - The Pharma Letter
Measuring Aquestive Therapeutics Inc.’s beta against major indicesEarnings Summary Report & Capital Efficient Trading Techniques - Newser
Aquestive Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha
Pullback Watch: What are Aquestive Therapeutics Inc.’s recent SEC filings showing2025 Retail Activity & Capital Efficiency Focused Ideas - خودرو بانک
Is Aquestive Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Capital Protection Trading Alerts - خودرو بانک
What are Aquestive Therapeutics Inc.’s recent SEC filings showingJuly 2025 Trends & Verified Swing Trading Watchlists - خودرو بانک
Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm - MSN
Aquestive Therapeutics' Strategic Path to Anaphylm Approval and Market Capture - AInvest
Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha
2.66%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):